NurExone Biologic Inc. raises C$1.2 million through private placement and warrant exercises

From GlobeNewswire: 2025-01-21 16:20:40

NurExone Biologic Inc. has closed a non-brokered private placement, raising C$479,917.76 through the sale of 856,996 units at C$0.56 per unit. Additionally, the company received C$727,755.04 from the exercise of 2,140,456 Class A Warrants at C$0.34 per warrant. The proceeds will be used for working capital purposes, subject to TSX Venture Exchange approval. Each unit sold consisted of one common share and one common share purchase warrant, allowing the holder to purchase one common share at C$0.70 within 36 months.

The successful fundraising efforts by NurExone Biologic Inc. have generated over C$1.2 million, providing crucial support for the company’s mission. Dr. Lior Shaltiel, the CEO, expressed gratitude for the investors’ trust and highlighted the importance of the warrant exercises and private placement in advancing the company’s vision and strategy. Additionally, the appointment of Dr. Tali Kizhner as the new Director of Research and Development will enhance NurExone’s R&D activities and collaborations, moving towards clinical trials and achieving key milestones.



Read more at GlobeNewswire: NurExone Secures C$1.2 Million through Warrant Exercises